浙江九洲药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603456 证券简称：九洲药业 公告编号：2023-084 三、公司参加人员 重要内容提示： 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2023 年 08 月 11 日（星期五） 至 08 月 17 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 一、说明会类型 浙江九洲药业股份有限公司（以下简称"公司"）将于 2023 年 8 月 15 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2023 年半年度报告。为便于广大 投资者更全面、深入地了解公司业绩和经营情况，公司计划于 2023 年 8 月 18 ...

证券代码：603456 证券简称：九洲药业 公告编号：2023-053 浙江九洲药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 11 日（星期四）15:00-16:30 会议召开方式：上证路演中心视频录播和网络互动 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2023 年 5 月 4 日（星期四）至 5 月 10 日（星期三）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 3、会议召开方式：上证路演中心视频录播和网络互动 三、公司参加人员 总裁梅义将先生；财务负责人沙裕杰先生；独立董事俞飚先生；董事、副总 裁兼董事会秘书林辉潞先 ...

Financial Performance - The company's operating revenue for 2022 was ¥5,445,105,154.77, representing a 34.01% increase compared to ¥4,063,181,915.60 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥920,922,206.88, a 45.28% increase from ¥633,900,939.63 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥927,011,401.18, reflecting a 61.70% increase from ¥573,287,858.62 in 2021[17]. - The net cash flow from operating activities for 2022 was ¥1,225,782,092.45, an 80.92% increase compared to ¥677,519,236.31 in 2021[17]. - The total assets at the end of 2022 were ¥7,913,275,762.32, a 12.40% increase from ¥7,040,423,684.10 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥5,296,559,223.73, which is a 15.72% increase from ¥4,577,129,753.17 in 2021[17]. - The company's operating revenue for 2022 reached 5.445 billion RMB, an increase of 34.01% compared to the previous year, primarily driven by the growth in CDMO business[25]. - Net profit attributable to shareholders for 2022 was 921 million RMB, reflecting a year-on-year increase of 45.28%, also mainly due to the expansion of CDMO business[25]. - Basic earnings per share for 2022 increased by 44.16% to 1.11 RMB per share, attributed to the rise in net profit[19]. - Diluted earnings per share rose by 46.05% to 1.11 RMB per share, driven by the increase in net profit attributable to shareholders[19]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares to all shareholders for the 2022 fiscal year, with no stock increases or bonus shares issued[2]. - The total cash dividend amount, including share repurchase, is RMB 406,451,648.86, which accounts for 44.14% of the net profit attributable to ordinary shareholders[151]. - The company plans to implement a shareholder return plan for the next three years (2022-2024)[127]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[2]. - The company has established a comprehensive quality management system that meets global industry standards, ensuring compliance with various international regulatory bodies[46]. - The company has continuously improved its internal control system to ensure compliance and asset security, aligning with regulatory requirements[158]. - The internal control audit report for the year was issued with a standard unqualified opinion by Tianjian Accounting Firm[160]. Research and Development - The company invested CNY 335 million in R&D in 2022, representing a 77.85% increase year-over-year[26]. - The total number of R&D personnel is 993, representing a significant investment in human resources for innovation and development[64]. - The R&D investment in CDMO projects was 19,330.76 million RMB, accounting for 3.55% of operating revenue, with a significant increase of 92.03% compared to the previous year[84]. - The company has developed multiple leading technology platforms, including chiral catalysis and continuous reaction technologies, to address client challenges[26]. - The company has established a comprehensive CDMO service platform for small molecule drugs, including pre-formulation, formulation development, quality research, and commercial production[42]. Market Expansion and Strategic Initiatives - Future outlook includes strategic plans for market expansion and potential mergers and acquisitions to strengthen its competitive position[9]. - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[9]. - The company aims to leverage new technologies in its product development processes to improve efficiency and effectiveness[9]. - The company is actively pursuing potential acquisitions to strengthen its market position and diversify its product portfolio[130]. - The company plans to develop a CRO platform to extend its value chain and enhance service capabilities for existing and potential clients[106]. Risk Management - The company has established a comprehensive risk management system to enhance the effectiveness of internal control and management of subsidiaries[159]. - The company faces risks related to the potential withdrawal or recall of major innovative drugs, which could impact demand for its services[110]. - The company is experiencing intensified market competition from both domestic and international pharmaceutical contract development and manufacturing organizations (CDMOs) due to new entrants and increased investment in local facilities[115]. - Environmental and safety risks are present in the production process, with potential for accidents if not managed properly, despite the company's commitment to EHS management systems[116]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[121]. - The company has established a robust investor relations management system to ensure timely and accurate communication with investors[122]. - The company has committed to fulfilling its obligations regarding the repurchase of shares and compensation for investors in case of any false statements or omissions in the IPO prospectus[184]. - The company has made commitments regarding the performance of its stock incentive plan, ensuring that any benefits obtained will be returned if there are false disclosures[187]. Environmental Responsibility - The company has implemented carbon reduction measures through the purchase of green electricity and the use of green chemical technologies[179]. - The company has developed green catalytic and synthesis technologies that significantly reduce waste emissions and energy consumption, supporting a sustainable development model[178]. - The company has established a closed-loop management system focusing on risk prevention and effective management[159]. - The company has continuously invested in environmental protection, including hardware investments and maintenance of pollution control equipment, since obtaining ISO14001 certification in 2002[178].

Financial Performance - The company's operating revenue for Q1 2023 reached ¥1,751,242,194.31, representing a year-on-year increase of 27.49%[4] - Net profit attributable to shareholders for Q1 2023 was ¥280,694,039.23, up 35.07% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥274,128,312.35, reflecting a growth of 40.19% year-on-year[4] - Operating profit for Q1 2023 was ¥349,452,953.25, up from ¥253,540,462.07 in Q1 2022, reflecting a growth of 37.8%[20] - Net profit for Q1 2023 was ¥279,457,100.43, compared to ¥207,376,991.20 in Q1 2022, representing an increase of 34.8%[20] - Total comprehensive income amounted to CNY 280,874,570.57, an increase from CNY 206,478,271.34 in the previous period, reflecting a growth of approximately 36%[21] - Basic and diluted earnings per share increased to CNY 0.32 from CNY 0.25, representing a growth of 28%[21] Cash Flow and Liquidity - The net cash flow from operating activities amounted to ¥456,884,062.19, an increase of 19.49% from the previous year[4] - As of March 31, 2023, the company's cash and cash equivalents amounted to approximately RMB 4.03 billion, a significant increase from RMB 1.10 billion as of December 31, 2022, representing a growth of 268%[15] - Cash inflow from operating activities reached CNY 2,098,706,912.05, up from CNY 1,666,898,204.18, indicating a growth of about 25.8%[23] - Net cash flow from operating activities was CNY 456,884,062.19, compared to CNY 382,358,482.10 in the previous year, marking an increase of approximately 19.5%[23] - Cash inflow from financing activities totaled CNY 3,174,999,971.42, significantly higher than CNY 683,816,779.30 in the prior year, showing an increase of over 367%[24] - The net increase in cash and cash equivalents was CNY 3,017,760,716.20, compared to CNY 420,117,429.98 in the previous period, reflecting a substantial growth of approximately 618%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,954,903,596.51, a 38.44% increase from the end of the previous year[4] - Total assets as of Q1 2023 were ¥10,954,903,596.51, compared to ¥7,913,275,762.32 in Q1 2022, marking an increase of 38.8%[18] - Total liabilities for Q1 2023 were ¥2,820,331,852.67, up from ¥2,541,795,984.35 in Q1 2022, reflecting a growth of 10.9%[17] - The company’s long-term borrowings rose to ¥157,975,147.77 in Q1 2023, compared to ¥83,991,508.88 in Q1 2022, indicating an increase of 88.0%[17] Shareholder Information - Shareholders' equity attributable to the parent company reached ¥8,060,888,128.40, marking a 52.19% increase year-on-year[5] - The total equity attributable to shareholders reached ¥8,060,888,128.40 in Q1 2023, compared to ¥5,296,559,223.73 in Q1 2022, an increase of 52.5%[17] - The total number of ordinary shareholders at the end of the reporting period was 33,368[9] - The top ten shareholders include Zhejiang Zhongbei Jiuzhou Group Co., Ltd. with a 31.52% stake and Taizhou Gede Industrial Co., Ltd. with a 4.51% stake[11] Investment and Growth Strategies - The company is focused on expanding its CDMO business, which has significantly contributed to the revenue growth[5] - The company completed a non-public offering of A-shares in January 2023, raising approximately RMB 2.49 billion after deducting underwriting fees[13] - The company used RMB 600 million of the raised funds to increase investment in its projects and RMB 1.46 billion to supplement working capital[13] - The acquisition of 100% equity in the Zhongshan formulation factory from Sandos (China) was completed in March 2023, enhancing the company's CDMO capabilities[14] - The company continues to enhance its project-oriented management model to deepen relationships with major clients and expand its customer base[5] Inventory and Receivables - Accounts receivable increased to approximately RMB 825.46 million from RMB 671.11 million, reflecting a growth of 23% year-over-year[15] - Inventory decreased to approximately RMB 1.79 billion from RMB 2.02 billion, indicating a reduction of 12%[15] Research and Development - Research and development expenses for Q1 2023 amounted to ¥78,769,888.33, up from ¥64,192,677.61 in Q1 2022, indicating a growth of 22.7%[19] Financial Management - The company reported a decrease in financial expenses from ¥12,518,148.32 in Q1 2022 to ¥7,883,702.45 in Q1 2023, a reduction of 37.5%[19] - The company’s deferred tax assets increased from ¥23,999,576.14 in Q1 2022 to ¥33,774,264.48 in Q1 2023, a growth of 40.9%[16] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[25]

Financial Performance - The company's operating revenue for Q3 2022 reached ¥1,418,207,438.23, representing a year-on-year increase of 24.83%[4] - The net profit attributable to shareholders for Q3 2022 was ¥275,166,576.91, up 38.77% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥294,301,623.25, reflecting a 54.11% increase year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.33, an increase of 37.50% compared to the same period last year[4] - The diluted earnings per share for Q3 2022 was also ¥0.33, reflecting a 37.50% increase year-on-year[4] - The company achieved a net profit of ¥743.23 million for the first three quarters of 2022, a growth of 57.09% year-on-year[6] - The total operating revenue for the first three quarters of 2022 reached ¥4,372,695,484.55, a significant increase of 45.5% compared to ¥3,004,229,474.76 in the same period of 2021[21] - The total profit for Q3 2022 was CNY 871,579,890.61, an increase of 60.1% from CNY 544,184,530.47 in Q3 2021[22] - The company’s operating profit for Q3 2022 was CNY 873,921,630.43, up from CNY 549,152,950.95 in Q3 2021, reflecting a growth of 59.0%[22] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥1,236,399,937.86, showing a significant increase of 191.42%[4] - As of September 30, 2022, cash and cash equivalents amounted to 1,495,710,632.14 RMB, an increase from 1,120,801,411.69 RMB at the end of 2021[17] - The cash and cash equivalents at the end of Q3 2022 amounted to CNY 1,077,953,018.45, up from CNY 858,721,339.25 at the end of Q3 2021, showing an increase of 25.6%[25] - The company's total assets as of the end of Q3 2022 amounted to ¥7,839,931,627.65, an increase of 11.36% from the end of the previous year[5] - The total current assets as of September 30, 2022, were 4,179,264,243.64 RMB, compared to 3,771,883,813.73 RMB at the end of 2021[17] - The company's accounts receivable decreased to 631,823,867.17 RMB from 767,032,258.42 RMB year-over-year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,481[10] - Zhejiang Zhongbei Jiuzhou Group Co., Ltd. holds 283,518,812 shares, accounting for 33.98% of total shares[10] - The top ten unrestricted shareholders include China Industrial Bank Co., Ltd. with 40,737,316 shares (4.88%) and Taizhou GeDe Industrial Co., Ltd. with 40,585,680 shares (4.86%)[11] Business Development - The strong performance was primarily driven by the growth in the CDMO business, supported by enhanced customer engagement and operational efficiency[6] - The company aims to achieve a one-stop capability from CMC research and development to commercial production in the CDMO industry[15] - The company signed an equity acquisition agreement with Sandos (China) Pharmaceutical Co., Ltd. to enhance its CDMO formulation business capabilities, with a fundraising amount of 185 million RMB[14] Expenses and Liabilities - Total operating costs for the first three quarters of 2022 were ¥3,439,860,576.73, up 39.0% from ¥2,472,370,398.44 in the previous year[21] - Research and development expenses increased to ¥227,413,281.50, representing an 86.5% rise from ¥122,104,944.00 in the prior year[21] - The total liabilities of the company were ¥2,633,390,645.01, up from ¥2,463,293,930.93, indicating a rise of 6.9%[19] - The equity attributable to shareholders reached ¥5,128,440,403.51, compared to ¥4,577,129,753.17, marking an increase of 12.0%[19] Tax and Investment Income - The company reported a tax expense of CNY 130,100,644.37 for Q3 2022, compared to CNY 70,801,890.24 in Q3 2021, which is an increase of 83.8%[22] - The company reported a net profit of ¥20,282,370.13 from investment income, down 54.8% from ¥44,792,103.57 in the previous year[21]

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders reached 300 million CNY, up 20% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was CNY 2,954,488,046.32, representing a 58.15% increase compared to CNY 1,868,124,056.33 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was CNY 468,062,251.01, a 70.31% increase from CNY 274,836,951.23 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 90.37%, reaching CNY 468,490,561.59 compared to CNY 246,089,231.34 last year[19]. - The net cash flow from operating activities surged by 306.04%, amounting to CNY 558,493,982.24, up from CNY 137,547,190.33 in the same period last year[20]. - Basic earnings per share rose by 69.70% to CNY 0.56, compared to CNY 0.33 in the previous year[21]. - The diluted earnings per share also increased by 69.70% to CNY 0.56, reflecting the growth in net profit attributable to shareholders[21]. - The total assets of the company reached CNY 7,928,191,347.80, a 28.51% increase from CNY 6,169,337,820.67 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 15.83% to CNY 4,853,799,419.55 from CNY 4,190,283,257.23 at the end of the previous year[20]. Market and Business Development - User data indicates a growth in active users by 25%, reaching 5 million active users by the end of June 2022[1]. - The company has set a revenue guidance of 2.5 billion CNY for the full year 2022, reflecting an expected growth of 10%[1]. - New product launches contributed to 30% of total revenue, with two major products introduced in Q2 2022[1]. - Market expansion efforts have led to a 40% increase in sales in the Southeast Asian market[1]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[1]. - The significant growth in revenue and profit is primarily attributed to the increase in CDMO (Contract Development and Manufacturing Organization) business[21]. - The company has strengthened its CDMO capabilities and optimized its internal management system, leading to improved profitability[29]. - The company is focusing on expanding its collaboration with both large and emerging pharmaceutical clients, resulting in a steady increase in orders and projects[29]. - The company is actively developing generic drugs and intermediates, leveraging its advantages in raw materials to create an integrated model for generic formulations[28]. - The company aims to enhance its market competitiveness by continuously optimizing production processes for clients' commercialized products[27]. Research and Development - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficacy and safety[1]. - R&D expenses surged by 102.26% year-on-year, totaling approximately ¥166.8 million, due to increased investments in CDMO and formulation R&D[60]. - The company has developed over 30 enzyme-catalyzed processes for active pharmaceutical ingredients and intermediates, emphasizing the advantages of mild reaction conditions and high selectivity[36]. - The company has established multiple leading technology platforms, including chiral catalysis and continuous reaction technology, which have been commercialized[34]. - The company has built a peptide platform with over 15 years of R&D experience, catering to custom peptide and new drug IND development[45]. Financial Management and Investments - The company has a strong talent management system, enhancing its ability to attract and retain skilled professionals in the pharmaceutical industry[39]. - The company launched a new stock incentive plan in March 2022 to enhance talent retention and align interests among shareholders, management, and core technical personnel[54]. - The company has implemented various talent development programs, including the "Navigator Plan" and "Wolf Warrior Plan," to enhance the capabilities of its workforce[54]. - The company completed the CMO multifunctional production base project, with a total investment of CNY 50,171.37 million, and the project was completed by June 30, 2022[72]. - The company acquired a 51% stake in Kangchuan Pharmaceutical, enhancing its CDMO formulation R&D capabilities[52]. Environmental and Social Responsibility - The company emphasizes green and sustainable development, focusing on low energy consumption and emissions, and is working towards carbon neutrality[41]. - The company has invested in advanced environmental protection technologies, including chiral catalytic and synthetic technologies, to significantly reduce waste emissions and energy consumption[114]. - The company has established a robust environmental risk emergency mechanism, ensuring efficient response to pollution incidents[109]. - The company has maintained compliance with environmental standards, with all monitored pollutants meeting discharge requirements[110]. - The company emphasizes its commitment to social responsibility, engaging in various charitable activities such as disaster relief and support for rural revitalization[116]. Risks and Challenges - The management highlighted risks related to regulatory changes that could impact future operations[1]. - The company faces risks related to the lifecycle changes of innovative drugs and potential market competition from generic drugs[79]. - There is a risk of technological upgrades in specialty raw materials affecting the company's main business[80]. - The company is exposed to regulatory changes in drug policies that could impact market access and competition[82]. - The competitive landscape is intensifying due to new entrants in the domestic market and increased foreign investment in local production[83]. Corporate Governance - The company did not distribute profits or increase capital reserves in the first half of 2022, with no dividends or stock bonuses declared[91]. - The company has not disclosed any significant contracts or their performance status during the reporting period[133]. - The company has not reported any non-standard audit opinions or changes in the previous year's annual report[126]. - The company has not engaged in any asset acquisitions or equity purchases during the reporting period[126]. - The company has no significant litigation or arbitration matters during the reporting period[126].

Financial Performance - The company's operating revenue for 2021 was ¥4,063,181,915.60, representing a 53.48% increase compared to ¥2,647,284,163.30 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥633,900,939.63, a 66.56% increase from ¥380,584,950.86 in 2020[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥573,287,858.62, up 77.86% from ¥322,327,811.34 in 2020[18]. - The net cash flow from operating activities increased by 69.21% to ¥677,519,236.31 in 2021 from ¥400,392,398.37 in 2020[18]. - The total assets of the company reached ¥7,040,423,684.10 in 2021, a 40.76% increase from ¥5,001,793,606.73 in 2020[18]. - The net assets attributable to shareholders were ¥4,577,129,753.17 in 2021, reflecting a 48.45% increase from ¥3,083,208,396.20 in 2020[18]. - The basic earnings per share for 2021 were ¥0.77, a 63.83% increase compared to ¥0.47 in 2020[19]. - The diluted earnings per share for 2021 were ¥0.76, up 61.70% from ¥0.47 in 2020[19]. - The weighted average return on equity for 2021 was 15.06%, an increase of 2.18 percentage points from 12.88% in 2020[19]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2.50 CNY per 10 shares to all shareholders for the 2021 fiscal year, with no stock increases or bonus shares issued[2]. - The company has not disclosed any significant changes in its share capital or shareholder situation during the reporting period[5]. - The total number of shares held by the chairman and general manager, Hua Lirong, remained unchanged at 31,904,260 shares[123]. - The total number of shares held by the independent directors remained unchanged, with each receiving a remuneration of 100,000 CNY[123]. - The company reported a total of 50,309,180 shares held at the beginning and end of the year, with a total remuneration of 17,121,000 CNY for all executives combined[124]. Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[2]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance[2]. - The company has not violated decision-making procedures for external guarantees[3]. - The financial report has been confirmed by the responsible persons, ensuring its authenticity and completeness[2]. - The company has not faced any situations where more than half of the directors cannot guarantee the accuracy of the annual report[3]. - The company has established a comprehensive governance structure in place, including a supervisory board that monitors compliance and financial health[116]. - The company has implemented a robust investor relations management system, ensuring timely and accurate responses to investor inquiries through various communication channels[116]. - The company adheres to strict information disclosure requirements, ensuring transparency and protecting shareholder rights[116]. Risk Management - The company has detailed potential risks in the report, which can be found in the "Management Discussion and Analysis" section[4]. - The report includes a forward-looking statement risk declaration, advising investors to be aware of investment risks[3]. - The company faces risks related to the potential delisting or large-scale recall of major innovative drugs it services, which could reduce demand for its APIs and intermediates[106]. - The company is exposed to market competition risks due to new entrants in the domestic market and increased investment from foreign pharmaceutical companies[109]. - The company has established a flexible pricing mechanism to mitigate significant exchange rate fluctuation risks, as a large portion of its business is overseas[112]. Research and Development - In 2021, the company achieved a research and development investment of 188 million yuan, a year-on-year increase of 65.01%[28]. - The company has established multiple leading technology platforms, including chiral catalysis and continuous reaction technology, enhancing its drug development capabilities[27]. - The company is focused on expanding its product portfolio through continuous R&D and innovation efforts[79]. - The company has multiple ongoing projects, including treatments for cardiovascular diseases, HIV, and various cancers, with GMP batch production and process validation in progress[83]. - The company has not canceled any major R&D projects during the reporting period, demonstrating a commitment to ongoing development efforts[83]. Acquisitions and Investments - The company acquired 100% of Hangzhou Zhuliang Pharmaceutical Technology Co., Ltd. and 51% of Nanjing Kangchuanji Pharmaceutical Co., Ltd. to enhance its small molecule innovative drug R&D capabilities[28]. - The company completed the acquisition of 51% equity in Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. for RMB 40 million, along with an additional capital increase of RMB 80 million[94]. - The company approved the acquisition of 100% equity in Taihua Pharmaceutical Chemical (Hangzhou) Co., Ltd. on November 22, 2021[134]. - The company has signed an agreement to acquire 100% equity of Teva Pharmaceutical Chemical (Hangzhou) Co., Ltd. for an estimated transaction price of approximately 34 million USD[152]. Environmental Responsibility - The company aims for carbon neutrality by 2030, focusing on green pharmaceutical technologies and reducing carbon emissions through process optimization[169]. - The company has implemented a comprehensive environmental monitoring plan, ensuring that all monitored pollutants meet discharge standards[165]. - The company has built RTO (Regenerative Thermal Oxidizer) facilities with treatment capacities of 25000m³/h and 20000m³/h at its two subsidiaries[162]. - The company has developed green catalytic and synthesis technologies, significantly reducing waste emissions and energy consumption[168]. Employee and Management - The company has a total of 4,083 employees, with 1,313 in the parent company and 2,770 in major subsidiaries[142]. - The company has a total of 184 employees with a master's degree or higher, reflecting a commitment to a qualified workforce[142]. - The company plans to enhance internal training programs and leadership training as part of its five-year human resources strategy[145]. - The company has implemented a stock incentive plan to retain and motivate key employees, which includes a total of 108,000 restricted shares[200]. Market Outlook - The global pharmaceutical market is projected to reach $1.8 trillion by 2026, with a compound annual growth rate (CAGR) of approximately 3-6% from 2022 to 2026[38]. - The global CDMO market is expected to grow by $165.57 billion from 2020 to 2027, with a CAGR of about 7.5%[39]. - The company aims to enhance its one-stop service capability in the CDMO field through independent R&D, deep cooperation, and mergers and acquisitions[102].

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,373,675,379.24, representing a year-on-year increase of 60.46%[4] - The net profit attributable to shareholders for Q1 2022 was ¥207,810,018.06, reflecting a significant increase of 120.13% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥195,536,741.57, up by 102.28% year-on-year[4] - Basic earnings per share for Q1 2022 were ¥0.25, an increase of 127.27% year-on-year[4] - Total operating revenue for Q1 2022 reached RMB 1,373,675,379.24, a significant increase of 60.4% compared to RMB 856,095,409.40 in Q1 2021[17] - Net profit for Q1 2022 was RMB 207,376,991.20, representing a 119.5% increase from RMB 94,680,696.08 in Q1 2021[18] - Total comprehensive income for Q1 2022 amounted to RMB 206,478,271.34, compared to RMB 93,295,524.19 in Q1 2021[19] Cash Flow - The net cash flow from operating activities reached ¥382,358,482.10, showing a dramatic increase of 3,701.30% compared to the previous year[4] - Cash flow from operating activities for Q1 2022 was RMB 382,358,482.10, a substantial increase from RMB 10,058,629.63 in Q1 2021[20] - The company reported a significant increase in cash received from sales and services, totaling RMB 1,393,123,966.88 in Q1 2022, compared to RMB 704,946,040.92 in Q1 2021[20] - The net increase in cash and cash equivalents was $420,117,429.98, compared to $407,343,149.54 in the prior period[22] - The ending balance of cash and cash equivalents reached $1,146,862,958.00, up from $662,168,970.28[22] Assets and Liabilities - The total assets at the end of Q1 2022 were ¥7,545,719,098.08, a 7.18% increase from the end of the previous year[5] - The equity attributable to shareholders at the end of Q1 2022 was ¥4,791,856,911.81, up by 4.69% from the previous year[5] - The company's current assets totaled RMB 4,191,022,995.91, up from RMB 3,771,883,813.73 at the end of 2021, indicating an increase of about 11.1%[14] - The company's total liabilities increased to RMB 2,745,405,077.88 from RMB 2,463,293,930.93, which is an increase of approximately 11.4%[15] - The equity attributable to shareholders of the parent company was RMB 4,791,856,911.81, up from RMB 4,577,129,753.17, representing an increase of about 4.7%[16] Research and Development - The company attributed its performance growth primarily to the strong increase in CDMO business, driven by expanded customer base and product pipeline[6] - The company continues to adhere to the highest international quality regulatory standards, focusing on accelerating the R&D of innovative drugs[5] - Research and development expenses increased to RMB 64,192,677.61 in Q1 2022, up 81.6% from RMB 35,357,842.45 in Q1 2021[17] - The company plans to continue investing in R&D to drive future growth and innovation[18] Investment and Financing Activities - Investment activities cash outflow totaled $195,678,925.38, an increase from $126,399,102.80 in the previous period[22] - Net cash flow from investment activities was -$163,723,600.90, compared to -$111,308,516.80 previously[22] - Cash inflow from financing activities amounted to $683,816,779.30, down from $1,388,999,985.39[22] - Net cash flow from financing activities was $202,303,178.95, a decrease from $508,118,012.53[22] - The company reported a cash outflow of $474,000,000.00 for debt repayment, down from $871,592,500.00[22] Other Financial Metrics - The weighted average return on equity increased by 1.95 percentage points to 4.44%[4] - Other comprehensive income after tax for Q1 2022 was RMB -898,719.86, an improvement from RMB -1,385,171.89 in Q1 2021[19] - The company completed the deregistration of its joint venture FJ Pharma, LLC in January 2022, which was approved by the board in April 2020[12] - The impact of exchange rate changes on cash and cash equivalents was -$820,630.17, contrasting with a positive impact of $475,024.18 in the previous period[22] - The company did not apply the new accounting standards for the first quarter of 2022[23]

Financial Performance - The company's revenue for Q3 2021 reached ¥1,136,105,418.43, representing a year-over-year increase of 53.97%[4] - Net profit attributable to shareholders for Q3 2021 was ¥198,285,197.31, an increase of 80.39% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥190,967,141.35, reflecting a significant increase of 111.40% year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.24, up 71.43% from the previous year[4] - Total operating revenue for the first three quarters of 2021 reached ¥3,004,229,474.76, a significant increase from ¥1,745,837,089.12 in the same period last year, representing a growth of approximately 72.0%[16] - Operating profit for the third quarter was ¥549,152,950.95, compared to ¥292,668,143.15 in the previous year, indicating an increase of about 87.6%[18] - Net profit attributable to shareholders of the parent company for the third quarter was ¥473,122,148.54, up from ¥239,369,327.15, reflecting a growth of approximately 97.5%[19] - The company reported a total comprehensive income of ¥472,082,866.15 for the third quarter, compared to ¥238,390,876.66 in the previous year, reflecting an increase of about 97.5%[19] Assets and Liabilities - The total assets as of the end of the reporting period amounted to ¥6,452,383,759.21, a 29.00% increase from the end of the previous year[5] - The total assets of the company reached ¥6,452,383,759.21, up from ¥5,001,793,606.73, marking an increase of about 29.1% year-over-year[15] - The total liabilities increased to ¥1,894,307,053.74, compared to ¥1,633,041,040.39 in the previous year, which is an increase of approximately 16%[15] - The total liabilities of the company stood at ¥1,915,677,518.46, with non-current liabilities totaling ¥282,636,478.07[16] - Total liabilities amounted to approximately ¥1,915.68 million, with current liabilities at ¥1,633.04 million and non-current liabilities at ¥282.64 million[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,490, with the largest shareholder, Zhejiang Zhongbei Jiuzhou Group Co., Ltd., holding 283,518,812 shares, accounting for 34.05% of the total[10] - The company has a total of 283,518,812 unrestricted shares held by its largest shareholder, indicating a strong position in the market[10] - Shareholders' equity totaled approximately ¥3,086.12 million, with total equity attributable to the parent company at ¥3,083.21 million[29] Cash Flow - The company reported a net cash flow from operating activities of ¥424,269,362.37, which is a 15.03% increase year-to-date[4] - Cash inflow from operating activities for the first three quarters of 2021 reached CNY 2,797,076,921.77, a significant increase of 54.0% compared to CNY 1,815,441,376.33 in the same period of 2020[21] - The net cash flow from operating activities for the first three quarters of 2021 was CNY 424,269,362.37, up from CNY 368,824,098.67 in 2020, reflecting a growth of 15.0%[21] - Cash inflow from financing activities in the first three quarters of 2021 totaled CNY 2,164,907,585.39, a substantial increase from CNY 971,811,250.00 in 2020, representing a growth of 123.0%[22] - The net cash flow from financing activities for the first three quarters of 2021 was CNY 589,917,139.54, compared to -CNY 9,280,876.43 in 2020, showing a positive turnaround[22] Investments and Acquisitions - The company completed the acquisition of 100% equity in Hangzhou Zhuliang Pharmaceutical Technology Co., Ltd. for ¥22,193,000, making it a wholly-owned subsidiary[12] - The company reported a significant increase in long-term equity investments, rising to ¥59,413,393.35 from ¥12,771,904.78, representing a growth of about 366.5%[14] Operational Costs and Expenses - The total operating cost for the first three quarters was ¥2,472,370,398.44, up from ¥1,508,400,770.52, indicating a rise of approximately 64.0%[16] - Research and development expenses for the third quarter amounted to ¥122,104,944.00, compared to ¥76,294,605.88 in the previous year, marking an increase of about 60.2%[18] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 4.62%, an increase of 0.82 percentage points year-over-year[5] - The company received government subsidies amounting to ¥5,228,196.48 during the reporting period, contributing to its financial performance[6] - The company recognized a right-of-use asset and lease liability of ¥1,799,993.16 due to the implementation of revised accounting standards[29] - The company has short-term borrowings of approximately ¥788.02 million and long-term borrowings of approximately ¥140.19 million[27] - The company reported accounts payable of approximately ¥411.34 million and other payables totaling approximately ¥106.63 million[27]

Financial Performance - The company reported a total revenue of 1.2 billion CNY for the first half of 2021, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders reached 300 million CNY, up 20% compared to the same period last year[1]. - The company's operating revenue for the first half of 2021 reached ¥1,868,124,056.33, representing an increase of 85.34% compared to the same period last year[9]. - The net profit attributable to shareholders of the listed company was ¥274,836,951.23, up 112.32% year-on-year[9]. - The net profit after deducting non-recurring gains and losses was ¥246,089,231.34, reflecting a growth of 103.49% compared to the previous year[10]. - The net cash flow from operating activities was ¥137,547,190.33, which is a significant increase of 210.62% from the same period last year[10]. - The company has outlined a future outlook projecting a revenue growth of 12% for the full year 2021[1]. - The management is optimistic about the future outlook and has set ambitious targets for the upcoming quarters[9]. Research and Development - Research and development expenses increased by 25% year-on-year, totaling 150 million CNY, reflecting the company's commitment to innovation[1]. - The company is committed to ongoing research and development to innovate and improve its product lines[9]. - The company has a comprehensive and efficient R&D platform that meets both Chinese and international regulatory requirements, enhancing its competitive edge in the market[32]. - The company has established multiple R&D and production bases in Taizhou, Suzhou, Hangzhou, and the United States, capable of scaling production from grams to tons[30]. - The company has developed a comprehensive high-potency API production line with multiple OEB4 and OEB5 level production facilities[31]. - The company has increased its R&D investment in Zhejiang Ruibo, expanding its R&D team and enhancing project engineering capabilities to meet growing project demands[46]. Market Expansion and Strategy - The company has expanded its user base by 10% in the first half of 2021, reaching a total of 5 million active users[1]. - The company plans to launch two new products in Q3 2021, aiming to capture an additional 5% market share in the pharmaceutical sector[1]. - The company continues to focus on expanding its market presence and enhancing its product offerings to drive further growth[9]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product offerings[1]. - The company has implemented a new marketing strategy focusing on digital channels, which is expected to increase customer engagement by 30%[1]. Financial Health and Assets - The total assets of the company at the end of the reporting period were ¥6,169,337,820.67, a 23.34% increase from the end of the previous year[10]. - The net assets attributable to shareholders of the listed company amounted to ¥4,190,283,257.23, marking a growth of 35.91% year-on-year[10]. - Cash and cash equivalents increased by 187.20% to ¥932,183,960.32, reflecting improved liquidity[56]. - The company reported a significant increase in contract liabilities by 85.71% to ¥42,271,944.23, indicating higher pre-received payments[56]. - The company’s total assets increased to CNY 6,169,337,820.67 as of June 30, 2021, up from CNY 5,001,793,606.73 at the end of 2020, representing a growth of approximately 23.3%[117]. Environmental and Compliance - The company has implemented a robust EHS management system to ensure employee health and safety, aligning with international standards[37]. - A comprehensive cGMP quality management system has been established, ensuring compliance with global regulatory standards and enhancing product quality assurance[38]. - The company has strengthened its environmental management by investing in new wastewater treatment facilities and updating RTO equipment[50]. - The company is committed to achieving carbon neutrality by 2030, implementing measures to reduce carbon emissions and promote green practices among employees[91]. - The company has passed multiple EHS audits from domestic and international clients, demonstrating compliance with environmental regulations[88]. Risks and Challenges - The company faces risks related to the potential recall of innovative drugs and the lifecycle changes of these drugs, which could impact sales and profit margins[63][64]. - Changes in domestic drug regulatory policies, such as the implementation of the MAH system and consistency evaluation for generic drugs, may lead to increased market competition and impact the company's performance if it fails to adapt[66]. - The company faces intensified market competition due to new entrants in the domestic market and increased investments from foreign pharmaceutical companies[67]. - The company is exposed to significant foreign exchange risks due to its high overseas business proportion, primarily involving USD and EUR transactions[69]. Shareholder and Governance - The board of directors has approved a profit distribution plan, proposing a cash dividend of 0.5 CNY per share[1]. - The company launched a 2021 restricted stock incentive plan to align the interests of shareholders, the company, and core team members[51]. - The company has committed to ensuring that executive compensation is linked to the performance of the company's return measures[96]. - The company has confirmed that it will not engage in any related party transactions that could harm the interests of the company or its investors[94]. Legal and Regulatory - The company ensures that the prospectus for its initial public offering (IPO) does not contain false records, misleading statements, or significant omissions, and will repurchase shares if any violations are identified by authorities[94]. - The company has committed to compensating investors for losses incurred due to any false records or misleading statements in the IPO prospectus, with measures including establishing an investor compensation fund[95]. - There are no significant lawsuits or arbitration matters during the reporting period[99].